Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Significant Decline in Short Interest

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 3,020,000 shares, a drop of 13.7% from the September 15th total of 3,500,000 shares. Based on an average trading volume of 346,000 shares, the days-to-cover ratio is presently 8.7 days.

Insider Activity

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Several large investors have recently added to or reduced their stakes in KROS. Redmile Group LLC purchased a new position in Keros Therapeutics during the first quarter valued at approximately $36,576,000. Darwin Global Management Ltd. raised its position in shares of Keros Therapeutics by 35.4% during the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after buying an additional 375,523 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Keros Therapeutics by 17.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after buying an additional 176,803 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Keros Therapeutics by 7.9% during the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after buying an additional 113,563 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its position in shares of Keros Therapeutics by 28.8% during the second quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company’s stock valued at $17,311,000 after buying an additional 84,810 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $60.39 on Wednesday. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00. The company has a market capitalization of $2.18 billion, a P/E ratio of -11.73 and a beta of 1.23. The firm’s 50 day simple moving average is $52.45 and its two-hundred day simple moving average is $52.01.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm had revenue of $0.04 million for the quarter. During the same quarter in the prior year, the company earned ($1.27) earnings per share. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KROS has been the topic of a number of recent analyst reports. Guggenheim initiated coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Truist Financial reissued a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Scotiabank initiated coverage on shares of Keros Therapeutics in a report on Wednesday. They issued a “sector outperform” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $90.63.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.